Program
dulpatatug
Also written as “HLX22” and “HLX87 + HLX22”.
In Fosun Pharma's pipeline, dulpatatug
. Its studies are mostly in Breast Neoplasms · Stomach Neoplasms, led by Fosun Pharma.
Furthest: phase 3, since Jul 25, 20246 company-led studies, 5 open or runningNext primary completion: Jun 1, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Fosun Pharma | 65 open or running | phase 3since Jul 25, 2024 | Apr 4, 2019 | Jun 1, 2027phase 3 · NCT06532006 |
- Named in Fosun Pharma’s own pipeline as
HLX22 (dulpatatug)
, phase 3, as of Sep 21, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 4, 2019First study: phase 1 study in Solid TumorFirst studyNCT03916094 · 11 enrolled · China
- May 21, 2021Phase 2 study in Stomach NeoplasmsNCT04908813 · 150 enrolled · China
- Jul 25, 2024Phase 3 study in Stomach NeoplasmsNCT06532006 · 550 planned · United States, Argentina, Australia and more
- Feb 12, 2025Phase 2 study in HER2-low Hormone Receptor Positive Breast CancerNCT06832202 · 50 planned · China
- Dec 8, 2025Phase 3 study in Breast NeoplasmsNCT07294508 · 706 planned · China
- Sep 13, 2026Phase 2 study in Breast NeoplasmsNCT07824869 · 90 planned
Ahead
- Jun 1, 2027Primary completion: phase 2 study in HER2-low Hormone Receptor Positive Breast CancerNCT06832202
- Jun 1, 2027Primary completion: phase 3 study in Stomach NeoplasmsNCT06532006
- Jan 15, 2028Primary completion: phase 3 study in Breast NeoplasmsNCT07294508
- Mar 31, 2028Primary completion: phase 2 study in Breast NeoplasmsNCT07824869
TargetBeta
“dulpatatug”the company's pipeline, read by Claude · source
“A humanized immunoglobulin (lg) G1 monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2), with potential immunomodulating and antineoplastic activity. Upon administration, dulpatatug targets and binds to HER2 on tumor cell surface. This may induce a cytotoxic T-…”NCIt, read by Claude
“A humanized immunoglobulin (lg) G1 monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2), ”NCIt, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07824869Breast Neoplasms | 2 | Not yet recruiting | Mar 31, 2028 | 90 |
| NCT07294508Breast Neoplasms · China | 3 | Recruiting | Jan 15, 2028 | 706 |
| NCT06832202HER2-low Hormone Receptor Positive Breast Cancer · China | 2 | Recruiting | Jun 1, 2027 | 50 |
| NCT06532006Stomach Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Jun 1, 2027 | 550 |
| NCT04908813Stomach Neoplasms · China | 2 | Active, not recruiting | Dec 2024 | 150 |
| NCT03916094Solid Tumor · China | 1 | Completed | Jan 4, 2021 | 11 |
How it is read
Names in the registry
- “HLX22”, 5 entries
- “HLX87 + HLX22”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 3 studies
- Stomach Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.